A PYMNTS Company

Spain: Sanctions possible against Grifols for failure to notify of merger

By  |  May 4, 2015

Spain’s competition watchdog, CNMC, has started investigation proceedings against Grifols SA, which may face fines and sanctions stemming from their failure to notify authorities of their merger and acquisitions plans.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The CNMC authorized the first phase of Grifols takeover of Novartis International’s blood transfusion diagnostics division, which was bought by the Spanish multinational on March 25. However, the CNMC would have received the formal notification documents only ten days prior, on March 10th.

    The relevant merger operations, meanwhile, would have taken place over one year prior, in early January 2014. Spain’s competition laws force businesses to notify the CNMC of any merger before it is carried out. Due to the timeline presented to the regulator, the CNMC has determined it necessary to investigate whether or not this rule was violated by the pharmaceuticals multinational.

    Full content: CNMC

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.